Sponsor
Novo Nordisk launches Wegovy in India, targets obesity treatment market, offers semaglutide-based weekly injection
Posted
Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 and Rs 26,050 per month, the injectable drug targets India's large obese population. The company aims to create awareness and collaborate with stakeholders to combat obesity, citing its significant impact on India's GDP.
Căutare
Categorii
- National
- International
- Business
- Technology
- Health
- Educaţie
- Sports
- Entertainment
- Travel
- Environment
- Science
- Law
- Agriculture
- Real Estate
- Opinion
- Religion
- Weather
- Automotive
- Social Issues
- Culture
- Sci-Fi & Future
Citeste mai mult
Gill 'didn't quite have that on-field aura' as Kohli, Rohit: Nasser Hussain
Following India's defeat in the Leeds Test, former England captain Nasser Hussain critiqued...
Prachanda raises alarm over bill tampering in parliament
KATHMANDU: Pushpa Kamal Dahal ‘Prachanda’, chair of Maoist Centre, has voiced serious...
NYC Mayoral polls: Democrat Zohran Mamdani wins primary, progressive economic ideas trump Cuomo; what's next?
In a stunning upset, Zohran Mamdani, a progressive state assemblyman, has emerged as the...